Sharma Dhruva, Sharma Neha, Sharma Preksha, Subramaniam Ganapathy
Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India.
Department of Pharmacology, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India.
J Educ Health Promot. 2021 Jan 28;10:31. doi: 10.4103/jehp.jehp_457_20. eCollection 2021.
In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became evident in Wuhan, China, and then spread rapidly worldwide. Numerous drugs and vaccines are under clinical trial pipeline for investigation against coronavirus disease 2019 (COVID-19) infection. The aim of this systematic review was to discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection. An exhaustive search was carried out for this review article including scientific databases of PubMed, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Web of Science, ScienceDirect, ProQuest, Google Scholar, and Scopus search engines using keywords of "Coronavirus," "COVID-19," "MERS-CoV," "MERS," "SARS-CoV-2," and "SARS-CoV-1" and "Solidarity trial" and their Persian-equivalent keywords from inception until May 2020. After screening the 296 articles searched from different databases (PubMed = 97 and other search engines = 199), 52 articles were included in the final systematic review. It was found that the World Health Organization introduced a Solidarity international clinical trial to discover an effectual treatment of COVID-19. Based on established and activity against different strains of coronaviruses, four repurposed drugs - remdesivir, lopinavir/ ritonavir combination, lopinavir/ritonavir with beta-1a, chloroquine, and hydroxychloroquine - were considered for clinical trial against COVID-19. A number of other drugs and vaccines are under clinical trial pipeline for investigation against COVID-19 infection. Despite multitude of treatment options available, treatment of choice is still not well established. Moreover, optimum supportive care and monitoring of seriously ill patients is the need of the hour.
2019年12月，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在中国武汉出现，随后迅速在全球传播。目前有许多药物和疫苗正处于针对2019冠状病毒病（COVID-19）感染的临床试验阶段。本系统评价的目的是讨论目前正在进行COVID-19感染试验的新型研究药物以及重新利用的药物。针对这篇综述文章进行了详尽的检索，包括使用关键词“冠状病毒”“COVID-19”“中东呼吸综合征冠状病毒（MERS-CoV）”“中东呼吸综合征（MERS）”“SARS-CoV-2”“SARS-CoV-1”以及“团结试验”及其波斯语等效关键词，检索了从创刊至2020年5月的PubMed、Embase、ClinicalTrials.gov、世界卫生组织国际临床试验注册平台、科学网、ScienceDirect、ProQuest、谷歌学术和Scopus等科学数据库。在筛选了从不同数据库检索到的296篇文章（PubMed = 97篇，其他搜索引擎 = 199篇）后，最终的系统评价纳入了52篇文章。结果发现，世界卫生组织开展了一项团结国际临床试验，以探寻COVID-19的有效治疗方法。基于已确立的对不同冠状病毒株的活性，四种重新利用的药物——瑞德西韦、洛匹那韦/利托那韦组合、洛匹那韦/利托那韦联合β-₁a、氯喹和羟氯喹——被考虑用于COVID-19的临床试验。还有许多其他药物和疫苗正处于针对COVID-19感染的临床试验阶段。尽管有多种治疗选择，但治疗的首选方案仍未明确确立。此外，对重症患者进行最佳的支持性护理和监测是当务之急。
